AndreyPopov Canadian pharmaceutical company Valeo Pharma ( OTCQB:VPHIF ) Thursday said that it has undertaken a restructuring of its commercial field operations aimed at improving margins, reducing operating expenses, aligning its commercial infrastructure with current market dynamics. Valeo Pharma ( OTCQB:VPHIF ) expects these cost reduction measures, including an approximate 20% downsizing of its workforce, will decrease its operating expenses by more than $5 million on an annualized basis. Combined with the previously implemented cost reduction measures announced in November 2023, total annualized costs savings from all measures will exceed $7.
0 million. "Although this restructuring was primarily focused on our Respiratory Group, we remain fully committed to our three specialty units, respiratory, ophthalmic and hospital," said Steve Saviuk, Valeo's CEO. Source: Press Release More on Valeo Pharma Historical earnings data for Valeo Pharma Financial information for Valeo Pharma.
